Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Retinoblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Monocytic, Acute 1Leukemia 1Hodgkin Disease 1Hepatoblastoma 1Febrile Neutropenia 1Fallopian Tube Neoplasms 1Chemotherapy-induced Neutropenia 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

pegfilgrastim 1NPI 2358 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Chemotherapy-induced Neutropenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡